Scientists in the United States have developed a new genetic technique that could potentially treat Down syndrome by silencing the extra chromosome responsible for the condition.
The approach targets chromosome 21, which is present in three copies in individuals with Down syndrome instead of the typical two. By using advanced gene-editing tools, researchers were able to deactivate the extra chromosome in laboratory settings, effectively reducing the genetic imbalance associated with the disorder.
According to reports from multiple Middle Eastern news outlets citing U.S.-based research, the method does not remove the chromosome but instead turns off its activity, preventing it from producing proteins that contribute to developmental and intellectual challenges linked to Down syndrome.
Experts involved in the study emphasized that while the technique shows promise in preclinical models, This proves still in early stages and has not yet been tested in humans. They cautioned that significant further research is needed before any potential therapeutic application could be considered.
The development represents a notable advancement in genetic medicine, offering a possible future pathway for addressing the root cause of Down syndrome rather than just managing its symptoms. Researchers noted that if proven safe and effective, such an approach could one day improve cognitive and health outcomes for individuals living with the condition.
Even though no clinical trials or human applications have been announced, the findings have drawn attention in scientific communities for their innovative use of gene silencing to address a chromosomal disorder that affects approximately one in every 700 babies born worldwide.
